BioSpace News Archive

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its selection as a finalist for presentation during the Innovation Showcase at the upcoming sixth annual Oncolytic Virotherapy Summit.

Inspiritol, Inc., a virtual pharmaceutical start-up filed a response with the FDA as part of their Investigational New Drug Application process for Inspiritol, a novel treatment for COVID-19, Long-COVID, and ME/CFS (Myalgic encephalomyelitis/chronic fatigue).

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced that it has launched the roadshow for its initial public offering of shares of its common stock.

Varian, a Siemens Healthineers company, and the Cincinnati Children’s/UC Health Proton Therapy Center today announced the completion of enrollment in FAST-01 (FeAsibility Study of FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases), the first human clinical trial of FLASH therapy.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), today presented a poster on Part 1, the open-label portion, of the study of SLS-002 (Intranasal Racemic Ketamine) at the IASR/AFSP International Summit on Suicide Research Virtual Conference.

At this year’s ASTRO 2021 event, GE Healthcare will showcase over 15 innovative multi-modality radiation therapy solutions, offering medical practitioners imaging tools and support they need to improve patient-centered care and advance the practice of precision medicine.

ADMA Biologics, Inc. announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 7.5 million shares of common stock.

Gritstone bio, Inc. today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December.

Revelation Biosciences Inc. (Revelation), announced today that it engaged Destum Partners Inc. to assist in finding an Ex-US development partner for its therapeutic product candidate REVTx-99, and development partner(s) worldwide for its therapeutic product candidate REVTx-200.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), announced today that is has closed its previously announced underwritten public offering of 8,712,400 shares of its common stock,